Rocket Lab (RKLB): Building the Whole Stack, Priced on One Launch

Thesis

I have held Rocket Lab since 2024 at around $7, so I want to be transparent about that up front. This is not me discovering a new name. It is me explaining why I am still a buyer after a violent move in both directions, and why I am adding rather than taking profits.

The reason starts with a misunderstanding I think most of the market still has about what Rocket Lab actually is. People file it under launch company. That undersells the strategy by a wide margin. Over the past few years, through seven acquisitions and a deliberate build-out, Rocket Lab has been assembling every single layer of the space stack in-house: propulsion, avionics, flight software, solar arrays, star trackers, reaction wheels, laser inter-satellite links from the Mynaric deal, and space robotics from Motiv. The Flatellite satellite they unveiled pulls all of it together into one mass-manufacturable spacecraft built almost entirely from their own proprietary components. Beck has said the goal is to build satellites at a rate approaching one a day. Almost no one else in the industry can do the entire stack internally.

That vertical integration is the whole point. It is what lets Rocket Lab win contracts historically reserved for legacy primes, and it is what sets up the real long-term prize, which I will get to.

Key Metrics

Comps

Rocket Lab has no clean valuation comp, and I think it is important to say that directly rather than construct a table that implies false precision. SpaceX is now public (SPCX) but operates at a scale and market dominance that makes it its own category, not a peer multiple. Legacy primes like Lockheed and Northrop are mature, slow-growing defense integrators priced accordingly. Pure-play peers like AST SpaceMobile and Intuitive Machines are pre-scale and command story multiples of their own. Rocket Lab sits in its own category as the most vertically integrated mid-cap pure-play in the space economy. That positioning is part of the thesis, and it is also part of why the market struggles to price it. There is no clean shortcut to a number from comps alone.

The Defense Anchor

Before the speculative upside, there is a real floor under this business, and it is the defense franchise. The clearest example: the $816M Space Development Agency Tranche 3 award, where Rocket Lab is the only commercial provider producing both the spacecraft and the payloads in-house for the SDA Tracking Layer. That is not a vendor role. That is a prime contractor position, won against the Lockheeds and Northrops of the world. Add the earlier $515M SDA Tranche 2 build, the $190M HASTE hypersonic contract that is the largest in company history, a missile-defense partnership with Raytheon, and an Air Force Neutron cargo mission, and you have a defense backlog that exists whether or not Neutron flies on schedule. That backlog, alongside the operating Electron and Space Systems businesses, is what defines my downside case. This company is not a story stock with no revenue. It did $200M last quarter, up 63% year over year, with a $2.2B backlog.

Electron Is the Proven Engine

Electron is the foundation the whole thesis stands on, and it is already proven. It is the most frequently launched US small rocket, with a long record of mission success, and it generates real revenue today while Neutron is still being developed. Its reliability also unlocks capabilities defense customers pay a premium for. Rocket Lab recently demonstrated true responsive launch, executing a Space Force mission on under 24 hours notice and getting it off the pad in under 17 hours. That kind of assured, rapid access to space is something very few providers can offer, and it is exactly what national security customers increasingly require. The point worth holding onto: the binary risk around Neutron sits on top of a core business that already works and already pays.

Customer demand also remains broad and continues to build years of visibility. In June 2026, NASA selected Rocket Lab for dedicated Electron launches of its PolSIR and TSIS-2 science missions under the 10-year VADR contract vehicle, with missions slated for early 2027. That win matters less for its size than for what it signals: civil science demand alongside the defense and commercial backlog, with three distinct customer bases, NASA, the Department of Defense, and commercial operators, all buying Electron. That diversification is itself a risk reducer.

Neutron Is the Swing Factor

Neutron is the binary event the entire valuation turns on. It is a medium-lift reusable rocket carrying 13,000kg to low Earth orbit, 43 times Electron’s payload, and it is aimed squarely at the market Falcon 9 dominates. But the more important detail is what Neutron is designed for: deploying constellations. Its wide fairing is built to carry stacks of flat satellites, and five commercial launch contracts are already signed before it has flown. First flight is targeted for Q4 2026.

I will be honest about the risk here rather than around it. Neutron has slipped before, from 2024, to mid-2025, to now. New rockets slip routinely, and a delay or a failed first flight is the single thing most likely to break the current valuation. The upside from a clean debut is partly priced in. A slip is not. That asymmetry is the core tension in owning this today, and I am not going to pretend it away.

The Real Prize

Here is the part that reframes everything and is the reason I hold rather than trade this. Every acquisition, Flatellite, and Neutron itself all point toward the same endgame: Rocket Lab deploying and operating its own satellite constellation, and selling services from space, not just selling rockets and satellites to other people. That is the Starlink playbook. The highest-margin, highest-multiple part of the entire space economy is recurring service revenue, not one-time launches. If Rocket Lab gets there, the addressable market is enormous. If it does not, it is still a strong launch, defense, and manufacturing business. That optionality, mostly unpriced today, is the ceiling on the bull case.

Why Now

The reason the entry point exists is almost entirely sentiment, not fundamentals, and that distinction is the whole basis for adding here. The stock ran to an all-time high of $151 in late May, then fell roughly 45% to the low $80s. The trigger was the SpaceX IPO, which pulled capital and attention out of the entire space sector, plus ordinary profit-taking after a 280% run. Over that same stretch, the business got better, not worse: record revenue, Nasdaq-100 inclusion, more defense awards. So the price fell for reasons external to the company while the fundamentals improved. That is the kind of dislocation I am willing to buy.

I want to be clear about what this is and is not. It is not cheap. The company is unprofitable, trades around $47B, and the backlog is a cleaner read on value than any earnings multiple right now. Insiders have also been net sellers, which I note as a real data point rather than explain away. This is a high-risk, catalyst-dependent position, not a value play.

Valuation: A Scenario Range

RKLB does not lend itself to a single price target, because one launch in Q4 2026 genuinely determines which world we are in. So I frame it as a range.

Downside (Neutron slips materially or fails): roughly $45 to $55. The defense backlog and existing businesses give a real floor, but the stock loses the premium the medium-lift and constellation opportunity justifies, and re-rates back toward where it traded before the run accelerated.

Base case (Neutron flies in 2026, defense cadence continues): roughly $95 to $115. This is broadly where analyst consensus clusters. It assumes Neutron reaches orbit on a reasonable timeline and the backlog keeps converting, without assuming perfection.

Upside (Neutron succeeds cleanly and constellation revenue begins ramping into 2027 to 2028): roughly $140 to $160 and beyond. This is the path where Rocket Lab becomes the genuine number two to SpaceX and starts converting signed intent into real medium-lift and services revenue.

The width of that range is the point, not a weakness. A tidy single number would misrepresent how binary the next twelve months are.

Status

This is a live, high-conviction but high-risk position for me, held since 2024 and added to on the recent weakness. I am underwriting it on a multi-year horizon, because the constellation-operator endgame is years out and capital-intensive, which also means continued dilution risk along the way. My conviction sits in the vertical integration and the defense floor. My caution sits in the Neutron timeline and the valuation. One additional risk worth naming plainly: a meaningful portion of the backlog depends on US government and defense appropriations, which are subject to shifting budget priorities and political cycles. A change in the funding environment for national-security space is a genuine risk to the growth trajectory, independent of the company’s execution. Sized accordingly.